Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab
Endokrynol Pol. 2024;75(1):117-118. doi: 10.5603/ep.97224.ABSTRACTNot required for Clinical Vignettes.PMID:38497401 | DOI:10.5603/ep.97224 (Source: Endokrynologia Polska)
Source: Endokrynologia Polska - March 18, 2024 Category: Endocrinology Authors: Joanna Rymuza Aleksander Ku ś Dorota Bia łas-Niedziela Monika Turczy ńska Dariusz K ęcik Tomasz Bednarczuk Source Type: research
Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab
Endokrynol Pol. 2024;75(1):117-118. doi: 10.5603/ep.97224.ABSTRACTNot required for Clinical Vignettes.PMID:38497401 | DOI:10.5603/ep.97224 (Source: Endokrynologia Polska)
Source: Endokrynologia Polska - March 18, 2024 Category: Endocrinology Authors: Joanna Rymuza Aleksander Ku ś Dorota Bia łas-Niedziela Monika Turczy ńska Dariusz K ęcik Tomasz Bednarczuk Source Type: research
Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab
Endokrynol Pol. 2024;75(1):117-118. doi: 10.5603/ep.97224.ABSTRACTNot required for Clinical Vignettes.PMID:38497401 | DOI:10.5603/ep.97224 (Source: Endokrynologia Polska)
Source: Endokrynologia Polska - March 18, 2024 Category: Endocrinology Authors: Joanna Rymuza Aleksander Ku ś Dorota Bia łas-Niedziela Monika Turczy ńska Dariusz K ęcik Tomasz Bednarczuk Source Type: research
Investigation into effects of tocilizumab and epoetin beta in rats with experimental sciatic nerve injury model
CONCLUSIONS: TCZ and EPO decreased nerve injury effects by increasing motor and sensory conduction velocities of the sciatic nerve. Biochemically, TCZ and EPO significantly increased Superoxide Dismutase, Catalase, and Glutathione peroxidase 4 levels while decreasing Lipid Peroxidation levels (p=0.001). Histopathologically, neuronal degeneration following nerve injury was decreased in the groups receiving TCZ and EPO (p=0.001). EPO and TCZ attenuate the adverse effects of nerve injury. However, the TCZ+EPO treatment favoured biochemical activities over tissue and functional activities. This has been confirmed functionally,...
Source: Tissue and Cell - March 17, 2024 Category: Cytology Authors: Aysun G üler Kanter Harun Ülger Ahmet Sarper Bozkurt Mehmet Tarak çıoğlu İbrahim Hanefi Özercan Hasan Ulusal Source Type: research
Investigation into effects of tocilizumab and epoetin beta in rats with experimental sciatic nerve injury model
CONCLUSIONS: TCZ and EPO decreased nerve injury effects by increasing motor and sensory conduction velocities of the sciatic nerve. Biochemically, TCZ and EPO significantly increased Superoxide Dismutase, Catalase, and Glutathione peroxidase 4 levels while decreasing Lipid Peroxidation levels (p=0.001). Histopathologically, neuronal degeneration following nerve injury was decreased in the groups receiving TCZ and EPO (p=0.001). EPO and TCZ attenuate the adverse effects of nerve injury. However, the TCZ+EPO treatment favoured biochemical activities over tissue and functional activities. This has been confirmed functionally,...
Source: Tissue and Cell - March 17, 2024 Category: Cytology Authors: Aysun G üler Kanter Harun Ülger Ahmet Sarper Bozkurt Mehmet Tarak çıoğlu İbrahim Hanefi Özercan Hasan Ulusal Source Type: research
Tocilizumab Failed to Reduce Mortality in Severe COVID-19 Patients: Results from a Randomized Controlled Clinical Trial
Iran J Allergy Asthma Immunol. 2024 Feb 11;23(1):82-96. doi: 10.18502/ijaai.v23i1.14956.ABSTRACTThe severe coronavirus disease 2019 (COVID-19) is associated with increased levels of blood interleukin (IL)-6. Therefore, it is hypothesized that modulating the levels or effects of IL-6 could diminish airway inflammation and alter the course of COVID-19. We conducted a controlled, randomized, double-blind clinical trial on hospitalized patients with severe COVID-19 in Iran. The patients were randomly distributed by block randomization to take either standard-of-care (SOC) plus 1 or 2 doses of tocilizumab 8 mg/kg or SOC alone. ...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 15, 2024 Category: Allergy & Immunology Authors: Mona Talaschian Maryam Akhtari Mahdi Mahmoudi Shayan Mostafaei Mohamadreza Jafary Seyyed Mostafa Jalali Kourosh Sadeghi Keivan Gohari Moghadam Hengameh Ansari Tadi Ahmadreza Jamshidi Source Type: research
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research
Tocilizumab Failed to Reduce Mortality in Severe COVID-19 Patients: Results from a Randomized Controlled Clinical Trial
Iran J Allergy Asthma Immunol. 2024 Feb 11;23(1):82-96. doi: 10.18502/ijaai.v23i1.14956.ABSTRACTThe severe coronavirus disease 2019 (COVID-19) is associated with increased levels of blood interleukin (IL)-6. Therefore, it is hypothesized that modulating the levels or effects of IL-6 could diminish airway inflammation and alter the course of COVID-19. We conducted a controlled, randomized, double-blind clinical trial on hospitalized patients with severe COVID-19 in Iran. The patients were randomly distributed by block randomization to take either standard-of-care (SOC) plus 1 or 2 doses of tocilizumab 8 mg/kg or SOC alone. ...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 15, 2024 Category: Allergy & Immunology Authors: Mona Talaschian Maryam Akhtari Mahdi Mahmoudi Shayan Mostafaei Mohamadreza Jafary Seyyed Mostafa Jalali Kourosh Sadeghi Keivan Gohari Moghadam Hengameh Ansari Tadi Ahmadreza Jamshidi Source Type: research
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research
Tocilizumab Failed to Reduce Mortality in Severe COVID-19 Patients: Results from a Randomized Controlled Clinical Trial
Iran J Allergy Asthma Immunol. 2024 Feb 11;23(1):82-96. doi: 10.18502/ijaai.v23i1.14956.ABSTRACTThe severe coronavirus disease 2019 (COVID-19) is associated with increased levels of blood interleukin (IL)-6. Therefore, it is hypothesized that modulating the levels or effects of IL-6 could diminish airway inflammation and alter the course of COVID-19. We conducted a controlled, randomized, double-blind clinical trial on hospitalized patients with severe COVID-19 in Iran. The patients were randomly distributed by block randomization to take either standard-of-care (SOC) plus 1 or 2 doses of tocilizumab 8 mg/kg or SOC alone. ...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 15, 2024 Category: Allergy & Immunology Authors: Mona Talaschian Maryam Akhtari Mahdi Mahmoudi Shayan Mostafaei Mohamadreza Jafary Seyyed Mostafa Jalali Kourosh Sadeghi Keivan Gohari Moghadam Hengameh Ansari Tadi Ahmadreza Jamshidi Source Type: research
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 | DOI:10.55563/clinexprheumatol/0znf7e (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research
Tocilizumab Failed to Reduce Mortality in Severe COVID-19 Patients: Results from a Randomized Controlled Clinical Trial
Iran J Allergy Asthma Immunol. 2024 Feb 11;23(1):82-96. doi: 10.18502/ijaai.v23i1.14956.ABSTRACTThe severe coronavirus disease 2019 (COVID-19) is associated with increased levels of blood interleukin (IL)-6. Therefore, it is hypothesized that modulating the levels or effects of IL-6 could diminish airway inflammation and alter the course of COVID-19. We conducted a controlled, randomized, double-blind clinical trial on hospitalized patients with severe COVID-19 in Iran. The patients were randomly distributed by block randomization to take either standard-of-care (SOC) plus 1 or 2 doses of tocilizumab 8 mg/kg or SOC alone. ...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 15, 2024 Category: Allergy & Immunology Authors: Mona Talaschian Maryam Akhtari Mahdi Mahmoudi Shayan Mostafaei Mohamadreza Jafary Seyyed Mostafa Jalali Kourosh Sadeghi Keivan Gohari Moghadam Hengameh Ansari Tadi Ahmadreza Jamshidi Source Type: research
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 | DOI:10.55563/clinexprheumatol/0znf7e (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research
Tocilizumab Failed to Reduce Mortality in Severe COVID-19 Patients: Results from a Randomized Controlled Clinical Trial
Iran J Allergy Asthma Immunol. 2024 Feb 11;23(1):82-96. doi: 10.18502/ijaai.v23i1.14956.ABSTRACTThe severe coronavirus disease 2019 (COVID-19) is associated with increased levels of blood interleukin (IL)-6. Therefore, it is hypothesized that modulating the levels or effects of IL-6 could diminish airway inflammation and alter the course of COVID-19. We conducted a controlled, randomized, double-blind clinical trial on hospitalized patients with severe COVID-19 in Iran. The patients were randomly distributed by block randomization to take either standard-of-care (SOC) plus 1 or 2 doses of tocilizumab 8 mg/kg or SOC alone. ...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 15, 2024 Category: Allergy & Immunology Authors: Mona Talaschian Maryam Akhtari Mahdi Mahmoudi Shayan Mostafaei Mohamadreza Jafary Seyyed Mostafa Jalali Kourosh Sadeghi Keivan Gohari Moghadam Hengameh Ansari Tadi Ahmadreza Jamshidi Source Type: research
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 | DOI:10.55563/clinexprheumatol/0znf7e (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research
